

Cardiovascular, Renal and Metabolic Clinical Development

A comprehensive approach to advancing CVRM therapies

Cardiovascular, Renal and Metabolic (CVRM) health represents the fastest expanding disease spectrum globally, linking cardiovascular diseases with related comorbidities, such as obesity, diabetes and chronic kidney disease. Due to shared risk factors, a better understanding of patient populations and interconnections of these conditions is needed for the best outcomes. To ensure clinical development success, expertise in your therapeutic area is essential. Our hand-selected team, experienced in your specific phase and indication, understands the nuances unique to each area, from patient recruitment strategies to regulatory pathways.

Combined disease area experience to de-risk and implement your study

IQVIA Biotech's CVRM project management team combines operational experience and deep expertise across cardiovascular, renal and metabolic health. By integrating real world data, we accelerate clinical development and foster strong partnerships for seamless trials. Our existing investigator relationships and institutional knowledge enhance our focus on biotech customers, bringing treatments to patients faster.

Operational expertise for CVRM studies

Over the past 5 years, IQVIA Biotech has provided clinical services to more than 500 studies ranging from Phase I to IV, across a broad spectrum of chronic and acute conditions including:

Cardiovascular

- Acute myocardial infarction
- Arrythmias
- Anti-coagulation
- Cardiomyopathy
- Congenital heart disease
- Heart failure
- Hypertension
- Hyperlipidemia/ hypercholesteremia/ dyslipidemia/ hypertriglyceridemia
- Pulmonary arterial hypertension (PAH)

Nephrology

- Alport syndrome
- Lupus nephritis
- Autosomal dominant polycystic kidney disease (ADPKD)
- Chronic kidney disease (CKD)
- Diabetic kidney disease (DKD)
- Vasculitis
- Focal segmental glomerular sclerosis (FSGS)

എ

- IgA nephropathy (Berger disease)
- Acute kidney injury

Endocrinology

- Obesity (including genetic variants)
- Type 1 diabetes
- Type 2 diabetes mellitus
- Growth hormone disorders
- Hypoparathyroidism
- Inborn errors of metabolism
- Post bariatric hypoglycemia
- Precocious puberty

Did you know?



Approximately 500 million people globally are affected by cardiovascular disease.⁽¹⁾

Globally, 80% of end-stage renal disease cases are caused by diabetes. hypertension or both.⁽²⁾



CVRM diseases remain underdiagnosed, undertreated and their interconnections under recognized.⁽³⁾

EARLY AND LATE PHASE EXPERTISE

IQVIA Biotech has staff with specific early phase and late phase experience to address the nuances of different phases of development and can grow with you as your pipeline matures.

A BIOTECH-SPECIALIZED CRO

IQVIA Biotech delivers flexible clinical solutions designed to help biotech and emerging biopharma companies get treatments to patients. Our clinical development team brings expertise from two decades of planning and executing clinical trials exclusively for biotech companies. Drawing on IQVIA's unparalleled data and advanced analytics, IQVIA Biotech creates intelligent connections to deliver powerful insights to help customers accelerate clinical development of innovative medical treatments.

Having a proactive and agile team with operational and therapeutic expertise aligned in helping meet your clinical research goals can be critical to successful development. Contact us to learn how our dedicated CVRM team can support your next study.

(1, National Library of Medicine. Circulation. 2022 Apr 26; 145(17): 1324–1338) (2, National Library of Medicine. 2022 Apr; 12(1): 7–11. Published online 2022 Mar 18) (3, Circulation Research. 2023;132:1050–1063.)



CONTACT US iqviabiotech.com